JP7280182B2 - バリアントＡｃｔＲＩＩＢタンパク質およびその使用 - Google Patents

バリアントＡｃｔＲＩＩＢタンパク質およびその使用 Download PDF

Info

Publication number
JP7280182B2
JP7280182B2 JP2019518302A JP2019518302A JP7280182B2 JP 7280182 B2 JP7280182 B2 JP 7280182B2 JP 2019518302 A JP2019518302 A JP 2019518302A JP 2019518302 A JP2019518302 A JP 2019518302A JP 7280182 B2 JP7280182 B2 JP 7280182B2
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
seq
actriib
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536440A (ja
JP2019536440A5 (https=
Inventor
ラビンドラ クマール，
アシャ グリンバーグ，
エリック エム． ヴォガン，
Original Assignee
アクセルロン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレイテッド filed Critical アクセルロン ファーマ インコーポレイテッド
Publication of JP2019536440A publication Critical patent/JP2019536440A/ja
Publication of JP2019536440A5 publication Critical patent/JP2019536440A5/ja
Priority to JP2023006458A priority Critical patent/JP7617962B2/ja
Application granted granted Critical
Publication of JP7280182B2 publication Critical patent/JP7280182B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019518302A 2016-10-05 2017-10-05 バリアントＡｃｔＲＩＩＢタンパク質およびその使用 Active JP7280182B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023006458A JP7617962B2 (ja) 2016-10-05 2023-01-19 バリアントＡｃｔＲＩＩＢタンパク質およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404718P 2016-10-05 2016-10-05
US62/404,718 2016-10-05
PCT/US2017/055421 WO2018067874A1 (en) 2016-10-05 2017-10-05 Variant actriib proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023006458A Division JP7617962B2 (ja) 2016-10-05 2023-01-19 バリアントＡｃｔＲＩＩＢタンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2019536440A JP2019536440A (ja) 2019-12-19
JP2019536440A5 JP2019536440A5 (https=) 2020-11-12
JP7280182B2 true JP7280182B2 (ja) 2023-05-23

Family

ID=61831930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019518302A Active JP7280182B2 (ja) 2016-10-05 2017-10-05 バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP2023006458A Active JP7617962B2 (ja) 2016-10-05 2023-01-19 バリアントＡｃｔＲＩＩＢタンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023006458A Active JP7617962B2 (ja) 2016-10-05 2023-01-19 バリアントＡｃｔＲＩＩＢタンパク質およびその使用

Country Status (10)

Country Link
US (2) US11267865B2 (https=)
EP (1) EP3523328A4 (https=)
JP (2) JP7280182B2 (https=)
KR (2) KR102761094B1 (https=)
CN (1) CN110036025B (https=)
AU (3) AU2017338916B2 (https=)
BR (1) BR112019006918A2 (https=)
CA (1) CA3039525A1 (https=)
MA (1) MA46471A (https=)
WO (1) WO2018067874A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023033573A (ja) * 2016-10-05 2023-03-10 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
US12103959B2 (en) 2018-05-03 2024-10-01 Acceleron Pharma Inc. Multispecific binders of TGFBeta-superfamily ligands and uses thereof
US12168683B2 (en) 2018-05-03 2024-12-17 Acceleron Pharma Inc. Binders of TGFβ-superfamily ligands and uses thereof
KR20250133994A (ko) * 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CA3103427A1 (en) * 2018-06-15 2019-12-19 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CN109293763B (zh) * 2018-10-26 2021-10-26 中国农业科学院特产研究所 水貂激活素b蛋白及其制备与应用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
MX2022009553A (es) * 2020-02-03 2022-11-07 Acceleron Pharma Inc Proteínas actriib variantes y sus usos.
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2021189010A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CA3179834A1 (en) * 2020-06-25 2021-12-30 David S. Block Ace2-fc fusion proteins and methods of use
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
WO2022150590A1 (en) * 2021-01-08 2022-07-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
JP2014530253A (ja) 2011-10-17 2014-11-17 アクセルロンファーマ， インコーポレイテッド 無効赤血球生成を処置するための方法および組成物
JP2016135141A (ja) 2007-02-02 2016-07-28 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
EP0169016B2 (en) 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
MXPA01007366A (es) 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
JP6157046B2 (ja) * 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP5719766B2 (ja) 2008-05-02 2015-05-20 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
AU2010282361B2 (en) 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
EP3202459B1 (en) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
EP3808778A1 (en) * 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
MA41920B1 (fr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CA3029890A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
CA3039573A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
AU2017338915B2 (en) 2016-10-05 2024-11-21 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
CN110036025B (zh) 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016135141A (ja) 2007-02-02 2016-07-28 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
JP2014530253A (ja) 2011-10-17 2014-11-17 アクセルロンファーマ， インコーポレイテッド 無効赤血球生成を処置するための方法および組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Greenwald J. et al.，Identification of a binding site on the type II activin receptor for activin and inhibin.，The Journal of biological chemistry，2000年，275(5)，3206-3212
SAKO Dianne et al.，Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB.，The Journal of biological chemistry，2010年，285(27)，21037-21048

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023033573A (ja) * 2016-10-05 2023-03-10 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP7617962B2 (ja) 2016-10-05 2025-01-20 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
US12240887B2 (en) 2016-10-05 2025-03-04 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof

Also Published As

Publication number Publication date
JP2019536440A (ja) 2019-12-19
WO2018067874A1 (en) 2018-04-12
US11267865B2 (en) 2022-03-08
CN110036025A (zh) 2019-07-19
AU2017338916A1 (en) 2019-04-18
US20220306724A1 (en) 2022-09-29
KR102595559B1 (ko) 2023-10-30
MA46471A (fr) 2021-05-19
JP7617962B2 (ja) 2025-01-20
CN110036025B (zh) 2024-03-22
AU2022201698A1 (en) 2022-04-07
US12240887B2 (en) 2025-03-04
KR20190073414A (ko) 2019-06-26
CA3039525A1 (en) 2018-04-12
KR102761094B1 (ko) 2025-02-03
JP2023033573A (ja) 2023-03-10
KR20230152811A (ko) 2023-11-03
BR112019006918A2 (pt) 2019-06-25
EP3523328A4 (en) 2020-04-01
EP3523328A1 (en) 2019-08-14
US20200055919A1 (en) 2020-02-20
AU2017338916B2 (en) 2022-03-24
AU2024200684A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
JP7617962B2 (ja) バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP7203807B2 (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7037363B2 (ja) Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用
JP7504947B2 (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP7219705B2 (ja) ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JP2019527547A5 (https=)
JP2023528709A (ja) バリアントａｃｔｒｉｉｂタンパク質およびその使用
HK40057061A (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK40011178A (zh) 变体actriib蛋白及其用途
HK40078293A (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
WO2019136043A1 (en) Single-arm co-receptor fusion proteins and uses thereof
HK1248732B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1252958B (zh) 单臂i型和ii型受体融合蛋白和其用途
HK1248733B (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
HK1203530A1 (en) Variants derived from actriib and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230119

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230126

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230206

TRDD Decision of grant or rejection written
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230330

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230511

R150 Certificate of patent or registration of utility model

Ref document number: 7280182

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150